AstraZeneca, vaccine will only be used for over 60s

“Astrazeneca will only be used for people over 60″. General Francesco Paolo Figliuolo said this, explaining that ” we currently have an audience of about 3.5 million over 60. We have to carry out the second dose which will be with AstraZeneca only for the over 60. For the rest, the second doses below the 60 years will be carried out with mRna vaccines, as well as the first doses “for under 60. Read also” In the changed epidemiological context, the CTS – in close dialogue with the Technical Scientific Commission of AIFA and with other health institutions – has considered appropriate to re-evaluate the indications for use of the AstraZeneca vaccine. The epidemiological scenario has changed, the relationship between benefits and potential risks changes not only according to the age of the people. Following an extraordinarily accurate, scrupulous and meticulous evaluation, the CTS has clearly recommended with regard to the first doses to reserve the AstraZeneca vaccine for those who are 60 years of age or older “, explained the coordinator of the Cts, Franco Locatelli. “For the age of less than 60 years, mRna vaccines are recommended. As regards the second dose of AstraZeneca, the indication can be summarized as follows: all available data indicate that thrombotic phenomena after the second dose are extraordinarily rare. However, given the availability of alternative vaccination platforms and inspired by a principle of maximum caution, supreme with respect to the health of Italians, it was decided to give a recommendation to use a second dose of the same vaccine for subjects over 60 years of age. For those under 60 years of age, it is recommended to consider the hypothesis of heterologous vaccination “for the second dose. The CTS recommendations on the AstraZeneca vaccine, which will only be given to over 60s, with booster with other mRna vaccines for young people who have already received the first dose, “they will be translated strictly”, clarified the Minister of Health, Roberto Speranza.